1. Home
  2. PMO vs CYBN Comparison

PMO vs CYBN Comparison

Compare PMO & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Municipal Opportunities Trust

PMO

Putnam Municipal Opportunities Trust

HOLD

Current Price

$10.39

Market Cap

294.3M

Sector

Finance

ML Signal

HOLD

Logo Cybin Inc.

CYBN

Cybin Inc.

HOLD

Current Price

$8.16

Market Cap

298.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMO
CYBN
Founded
1993
2019
Country
United States
Canada
Employees
N/A
N/A
Industry
Finance Companies
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
294.3M
298.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PMO
CYBN
Price
$10.39
$8.16
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$74.50
AVG Volume (30 Days)
99.0K
748.5K
Earning Date
01-01-0001
02-10-2026
Dividend Yield
4.10%
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$24.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.57
$4.81
52 Week High
$10.68
$10.73

Technical Indicators

Market Signals
Indicator
PMO
CYBN
Relative Strength Index (RSI) 45.34 77.32
Support Level $10.31 $6.53
Resistance Level $10.47 $7.21
Average True Range (ATR) 0.09 0.46
MACD -0.01 0.21
Stochastic Oscillator 25.81 96.59

Price Performance

Historical Comparison
PMO
CYBN

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.

About CYBN Cybin Inc.

Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

Share on Social Networks: